All In Biotech

Drug Trial Radar · NCT02409667

Plaque Psoriasis Efficacy and Safety With Secukinumab

Long Term Clear Skin Maintenance Treatment Optimization in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Multicenter, Open-label With Blinded-assessment, Comparative, 52 Week Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg s.c.

Last checked: Nov 20, 2026Latest source record: May 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 16,487 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

16,487

Actual

Start

May 7, 2015

Primary completion

Mar 14, 2017

Study completion May 8, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.

Conditions

  • Plaque Psoriasis

Interventions

  • SecukinumabBiological

    Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24Time frame: Week 52

Locations

200 sites in 24 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Innsbruck, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Loverval, Belgium

  • Novartis Investigative Site

    Jette, Brussels Capital, Belgium

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Stara Zagora, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Sofia, BGR, Bulgaria

  • Novartis Investigative Site

    Ivanić-Grad, Croatia

  • Novartis Investigative Site

    Osijek, Croatia

  • Novartis Investigative Site

    Zagreb, Croatia

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Brno, Czech Republic, Czechia

  • Novartis Investigative Site

    Ostrava Poruba, Czech Republic, Czechia

  • Novartis Investigative Site

    Prague, Czech Republic, Czechia

  • Novartis Investigative Site

    Arhus C, Denmark

  • Novartis Investigative Site

    Hellerup, Denmark

  • Novartis Investigative Site

    Tampere, Finland

  • Novartis Investigative Site

    Turku, Finland

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Grenoble, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Rouen, France

  • Novartis Investigative Site

    Saint-Etienne, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Trévenans, France

Showing 40 of 200 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.